Crizotinib as a Personalized Alternative for Targeted Anaplastic Lymphoma Kinase Rearrangement in Previously Treated Patients With non-Small-Cell Lung Cancer
Drug Design, Development and Therapy- New Zealand
doi 10.2147/dddt.s91988
Full Text
Abstract
Available in
Date
October 1, 2015
Authors
Publisher
Informa UK Limited